MaxCyte, Inc. To Present At 3rd Annual Regen Med Investor Day
Gaithersburg, MD, March 24, 2015 – MaxCyte® Inc., the pioneer in cell therapies using scalable, high-performance cell transfection systems, today announces that Chief Executive Officer Doug Doerfler will present at the 3rd Annual Regen Med Investor Day, on Wednesday, March 25, 2015 in New York City.
Mr. Doerfler will present at 3:10pm ET and 4.05pm ET to attending investors. During his presentation, Mr. Doerfler will discuss MaxCyte’s expertise in the discovery, development, manufacture, and delivery of innovative cell therapies utilizing best in class cell modification technologies. Specifically, he will present information on MaxCyte’s unique approach to CAR T-cell therapy, which dramatically reduces manufacturing time and expense and allows targeting of solid tumor cancers without the toxicity that limits other CAR therapies to hematological cancers.
“MaxCyte’s process is virus-free, cGMP-compliant, and can be completed in a matter of hours as opposed to days or weeks,” stated Mr. Doerfler. “MaxCyte’s flow electroporation technology solves current manufacturing challenges with a consistent, scalable manufacturing platform that is cost-effective and provides a clear path to commercialization.” Details of the MaxCyte presentation are as follows:
Event: ARM’s Regen Med Investor Day
Date: March 25, 2015
Time: 3.10pm ET (7.10pm GMT)
4.05pm ET (8.05pm GMT)
Location: Metropolitan Club, One East 60th Street, New York, NY 10022
At the time of the ARM Regen Med Investor Day, a live-streaming webcast of all panels and company presentations will be available at: http://www.arminvestorday.com/webcast and will be published on the event’s website shortly after the conference as well as on the company’s website at http://www.maxcyte.com/resources/videos-webinars.php.
About MaxCyte
MaxCyte is a world leader in the discovery, development, manufacture, and delivery of innovative cell therapies utilizing best in class cell modification technologies.
MaxCyte has developed a next-generation technology–flow electroporation–for the rapid engineering of human cells as therapeutics, enabling the development of safer, more effective and lower cost cell-based therapies for a broad range of applications with blockbuster commercial potential. The company currently has clinical, pre-clinical-partnered, and proprietary products under development and is presently involved in more than a dozen trials.
The MaxCyte GT® Flow Transfection System is a universal platform for the rapid, automated loading of CAR-modified mRNA into peripheral blood cells, which avoids the time and cost-intensive cell expansion process. The loading of fresh patient cells with CAR mRNA harnesses immune cells for targeted killing of tumors. This anti-tumor activity is not dependent on the patient’s immune system and is independent of cell surface concentration of the tumor antigen.
The Company also markets a portfolio of products and services that include the MaxCyte STX® Scalable Transfection System and MaxCyte VLX® Large Scale Transfection System. These platforms are used in drug discovery research and screening and protein production environments by 10 of the top 15 pharma companies worldwide as well as the top three in Japan. MaxCyte products enable the rapid development and consistent production of billions of (co)transfected primary cells, stem cells, and cell lines for protein and antibody production, rapid response vaccine development, and for cell-based assays with comparable results and Seamless Scalability™ from the bench to HTS and pilot and production scale.
For more information, www.maxcyte.com.
Contact: Meg Duskin
Marketing Communications Manager
301-944-1645
mduskin@maxcyte.com
Mr. Doerfler will present at 3:10pm ET and 4.05pm ET to attending investors. During his presentation, Mr. Doerfler will discuss MaxCyte’s expertise in the discovery, development, manufacture, and delivery of innovative cell therapies utilizing best in class cell modification technologies. Specifically, he will present information on MaxCyte’s unique approach to CAR T-cell therapy, which dramatically reduces manufacturing time and expense and allows targeting of solid tumor cancers without the toxicity that limits other CAR therapies to hematological cancers.
“MaxCyte’s process is virus-free, cGMP-compliant, and can be completed in a matter of hours as opposed to days or weeks,” stated Mr. Doerfler. “MaxCyte’s flow electroporation technology solves current manufacturing challenges with a consistent, scalable manufacturing platform that is cost-effective and provides a clear path to commercialization.” Details of the MaxCyte presentation are as follows:
Event: ARM’s Regen Med Investor Day
Date: March 25, 2015
Time: 3.10pm ET (7.10pm GMT)
4.05pm ET (8.05pm GMT)
Location: Metropolitan Club, One East 60th Street, New York, NY 10022
At the time of the ARM Regen Med Investor Day, a live-streaming webcast of all panels and company presentations will be available at: http://www.arminvestorday.com/webcast and will be published on the event’s website shortly after the conference as well as on the company’s website at http://www.maxcyte.com/resources/videos-webinars.php.
About MaxCyte
MaxCyte is a world leader in the discovery, development, manufacture, and delivery of innovative cell therapies utilizing best in class cell modification technologies.
MaxCyte has developed a next-generation technology–flow electroporation–for the rapid engineering of human cells as therapeutics, enabling the development of safer, more effective and lower cost cell-based therapies for a broad range of applications with blockbuster commercial potential. The company currently has clinical, pre-clinical-partnered, and proprietary products under development and is presently involved in more than a dozen trials.
The MaxCyte GT® Flow Transfection System is a universal platform for the rapid, automated loading of CAR-modified mRNA into peripheral blood cells, which avoids the time and cost-intensive cell expansion process. The loading of fresh patient cells with CAR mRNA harnesses immune cells for targeted killing of tumors. This anti-tumor activity is not dependent on the patient’s immune system and is independent of cell surface concentration of the tumor antigen.
The Company also markets a portfolio of products and services that include the MaxCyte STX® Scalable Transfection System and MaxCyte VLX® Large Scale Transfection System. These platforms are used in drug discovery research and screening and protein production environments by 10 of the top 15 pharma companies worldwide as well as the top three in Japan. MaxCyte products enable the rapid development and consistent production of billions of (co)transfected primary cells, stem cells, and cell lines for protein and antibody production, rapid response vaccine development, and for cell-based assays with comparable results and Seamless Scalability™ from the bench to HTS and pilot and production scale.
For more information, www.maxcyte.com.
Contact: Meg Duskin
Marketing Communications Manager
301-944-1645
mduskin@maxcyte.com